BioMimetic Therapeutics Ranked 181 Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500
Nov. 18, 2008
|
|
|
BioMimetic Therapeutics Reports 2008 Third Quarter Results
Nov. 11, 2008
|
|
|
BioMimetic Therapeutics to Report 2008 Third Quarter Financial Results on November 10
Nov. 6, 2008
|
|
|
BioMimetic Therapeutics Reports Promising Clinical Results Using Augment Injectable Bone Graft to Treat Distal Radius Fractures; Enrollment in North American Augment Pivotal Trial Accelerates; 314 of 396 Patients Enrolled
Nov. 3, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the BIO Investor Forum
Oct. 28, 2008
|
|
|
BioMimetic Therapeutics Adds $39 Million of Liquidity; Reaches Agreement with Deutsche Bank to Provide Credit Facility using Auction-Rate Securities as Collateral
Oct. 28, 2008
|
|
|
BioMimetic Therapeutics Announces No Changes Requested by Independent Data Monitoring Committee to Pivotal Trial Design for Augment™ Bone Graft; 268 of 396 Patients Enrolled to Date in U.S. Pivotal Trial
Sep. 23, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the UBS Global Life Sciences Conference
Sep. 22, 2008
|
|
|
BioMimetic Therapeutics Reports 2008 Second Quarter Results; Positive Results Achieved with Augment™ Injectable Bone Graft to Enhance Healing in Foot and Ankle Fusions
Aug. 12, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Canaccord Adams Global Growth Conference
Aug. 8, 2008
|
|
|
BioMimetic Therapeutics to Report 2008 Second Quarter Financial Results on August 11; Company to Release Results of Augment Injectable Bone Graft in Foot and Ankle Fusions
Aug. 6, 2008
|
|
|
BioMimetic Therapeutics Launches Augment™ as the New Brand Name for the Company's Orthopedic Product Line; Clinical Investigator to Present Canadian Trial Results at AOFAS Meeting
June 19, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Jefferies 2nd Annual Healthcare Conference
June 20, 2008
|
|
|
BioMimetic Therapeutics Announces Highlights from Annual Meeting of Stockholders
June 12, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Bank of America Securities 2008 Healthcare Conference
May 13, 2008
|
|
|
BioMimetic Therapeutics Releases First Quarter Earnings Results; $33.4 Million Cash Received from the Sale of Orofacial Therapeutic Business
May 8, 2008
|
|
|
BioMimetic Therapeutics to Report 2008 First Quarter Financial Results on May 8
May 7, 2008
|
|
|
BioMimetic Therapeutics Receives Written Communication from FDA Confirming Status of Ongoing Pivotal Trial for GEM OS1; No Changes Recommended to Trial Design
March 27, 2008
|
|
|
BioMimetic Therapeutics Addresses FDA Communication on Regranex Safety Review
March 27, 2008
|
|
|
BioMimetic Therapeutics Reports 2007 Fourth Quarter and Year-end Results; Year Marked by Strong Cash Position, Positive Orthopedic Data and Progressing Clinical Trials
March 12, 2008
|
|
|
BioMimetic Therapeutics, Inc. Provides Updates on Clinical and Preclinical Activities; Company Receives Go Ahead from Health Canada to File GEM OS1 DLA
March 7, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Clinical and Preclinical Activities at ORS and AAOS Meetings
Feb. 29, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Deutsche Bank Small and Mid Cap Growth Conference
Feb. 14, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Present at BIO CEO and Investor Conference
Feb. 14, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Wachovia Healthcare Research Conference
Jan. 29, 2008
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Stanford Group Company Annual Healthcare Conference
Jan. 15, 2008
|
|
|
BioMimetic Therapeutics Closes on Transaction to Sell Remaining Dental Business
Jan. 7, 2008
|
|
|
BioMimetic Therapeutics to Sell Remaining Dental Business for Additional $40 Million Cash plus Continuation of Royalties; Company to Focus on Orthopedics, Spine and Sports Medicine
Dec. 17, 2007
|
|
|
BioMimetic Therapeutics Reports Positive Clinical Results for GEM OS®1 in Canadian Foot and Ankle Fusion Study; Clinical Success Rate of 90% Achieved in a High Risk Patient Population
Dec. 13, 2007
|
|
|
BioMimetic Therapeutics to Provide Results for GEM OS®1 Canadian Foot and Ankle Fusion Study; Company to host Conference Call on December 13 to Discuss Study Findings
Dec. 12, 2007
|
|
|
BioMimetic Therapeutics Reports 2007 Third Quarter Results
Nov. 13, 2007
|
|
|
BioMimetic Therapeutics to Report 2007 Third Quarter Financial Results on November 13
Nov. 8, 2007
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Nov. 5, 2007
|
|
|
BioMimetic Therapeutics' Study to Receive Award for Outstanding Publication from American Academy of Periodontology
Oct. 30, 2007
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at BIO InvestorForum 2007
Oct. 5, 2007
|
|
|
BioMimetic Therapeutics Reports 2007 Second Quarter Results
Aug. 14, 2007
|
|
|
BioMimetic Therapeutics to Report 2007 Second Quarter Financial Results on August 14
Aug. 9, 2007
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Canaccord Adams' 27th Annual Global Growth Conference
Aug. 7, 2007
|
|
|
BioMimetic Therapeutics' Clinical Investigator Presents
Positive Interim Data on U.S. and Canadian Foot and Ankle Clinical Trials
July 13, 2007
|
|
|
BioMimetic Therapeutics' Clinical Investigator to Present Update of Orthopedic Clinical Results from U.S. and Canadian Trials; Company to host Conference Call on July 13 to Discuss Study Findings
July 10, 2007
|
|
|
BioMimetic Therapeutics Announces Highlights from Inaugural Annual Meeting of Stockholders
June 21, 2007
|
|
|
BioMimetic Therapeutics Initiates Enrollment in E.U. Registration Trial for GEM OS®1 Bone Graft; U.S. GEM OS1 Pivotal Study Protocol Amended to Allow Shorter Follow-Up Time and More Patients
June 7, 2007
|
|
|
BioMimetic Therapeutics Reports 2007 First Quarter Results; Company Added to NASDAQ Biotechnology Index
May 14, 2007
|
|
|
BioMimetic Therapeutics to Report 2007 First Quarter Financial Results on May 14
May 11, 2007
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at the Deutsche Bank 32nd Annual Health Care Conference
May 1, 2007
|
|
|
BioMimetic Therapeutics Reports 2006 Fourth Quarter and Year-end Results; Company Receives Clearance to Initiate Enrollment in GEM OS1 US Pivotal Trial
March 28, 2007
|
|
|
BioMimetic Therapeutics to Report 2006 Year End Financial Results on March 28
March 22, 2007
|
|
|
BioMimetic Therapeutics Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteonecrosis of the Jaw
Feb. 21, 2007
|
|
|
BioMimetic Therapeutics, Inc. Completes Public Offering of Approximately 3.25 Million Shares of Common Stock Including the Sale of All Over-Allotment Shares
Feb. 14, 2007
|
|
|
BioMimetic Therapeutics, Inc. Announces Pricing of Public Offering
Feb. 12, 2007
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Upcoming Conferences
Feb. 9, 2007
|
|
|
BioMimetic Therapeutics Reports Positive Clinical Results
Using GEM OS®1 to Treat Distal Radius Fractures
Jan. 25, 2007
|
|
|
BioMimetic Therapeutics Announces Positive Results;
GEM OS1 Stimulates Bone Healing Comparable to Autograft
Dec. 13, 2006
|
|
|
BioMimetic Therapeutics to Announce Interim U.S. Clinical Trial Results for GEM OS1;
Press Release and Conference Call Scheduled for Dec. 13
Dec. 12, 2006
|
|
|
BioMimetic Therapeutics Reports Third Quarter 2006 Results
Nov. 6, 2006
|
|
|
BioMimetic Therapeutics' Clinical Investigator Highlights Results
of Orthopedic Clinical Trial in Canada
Nov. 6, 2006
|
|
|
BioMimetic Therapeutics' Clinical Investigator to Present Orthopedic Clinical Results
from Canadian Trial on November 4; Company to Report Third Quarter Financial Results
Nov. 2, 2006
|
|
|
BioMimetic Therapeutics Receives FDA Approval that Expands Manufacturing Capacity
for GEM 21S® ; Approval of rhPDGF-BB Manufacturing Facility
Oct. 13, 2006
|
|
|
BioMimetic Therapeutics Adds Key Talent to Board of Directors
Sep. 27, 2006
|
|
|
BioMimetic Therapeutics' Clinical Investigator Provides Results Demonstrating
Long-Term Efficacy for GEM 21S Treatment; Data Shows Continued Benefits
in Bone Growth for up to 2 Years after Treatement
Sep. 18, 2006
|
|
|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities
at the AG Edwards Emerging Growth Conference
Sep. 15, 2006
|
|
|
BioMimetic Therapeutics' Clinical Investigators to Receive Award
from American Academy of Periodontology for Outstanding Publication;
Clinical Investigators to Present Data at Annual AAP Meeting
Sep. 14, 2006
|
|
|
BioMimetic Therapeutics Reports Second Quarter 2006 Results;
Orthopedic Clinical Trial Progress Highlights 2006 Second Quarter
Aug. 9, 2006
|
|
|
BioMimetic Therapeutics Posts Webcast re: Second Quarter 2006 Financial Results
Aug. 9, 2006
|
|
|
BioMimetic Therapeutics Successfully Completes Enrollment in Three Orthopedic
Pilot Clinical Trials for GEM OS1™ Bone Graft; Canadian Study Expanded to 60 Patients
July 11, 2006
|
|
|
BioMimetic Therapeutics to Highlight Corporate Activities
at Pacific Growth Equities Life Science Growth Conference
June 8, 2006
|
|
|
BioMimetic Therapeutics Receives Approval to Market
GEM 21S® Growth-factor Enhanced Matrix in Canada
June 7, 2006
|
|
|
Dr. Samuel E. Lynch Presides Over the NASDAQ Closing Bell to Celebrate
the Initial Public Offering of BioMimetic Therapeutics, Inc. [BMTI]
March 20, 2006
|
|
|
BioMimetic Therapeutics, Inc. Announces Pricing of Initial Public Offering
May 12, 2006
|
|
|
BioMimetic Therapeutics Initiates Clinical Trials with Novel
Bio-Active Drug-device Combination Bone Graft in Two Orthopedic Indications
March 20, 2006
|
|
|
BioMimetic Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Feb. 10, 2006
|
|
|
BioMimetic Therapeutics Announces FDA Approval of GEM 21S®
Growth-factor Enhanced Matrix for the Treatment of Periodontally-related Bone Defects
Nov. 21, 2005
|
|
|
BioMimetic Therapeutics Appoints Larry W. Papasan and James G. Murphy to its Board of Directors
Oct. 12, 2005
|
|
|
BioMimetic Pharmaceuticals Strengthens Senior Leadership Team
July 13, 2005
|
|
|
BioMimetic Pharmaceuticals, Inc. Closes Series B Venture Funding
May 21, 2005
|
|
|
BioMimetic Pharmaceuticals Raises Additional $11.8 Million in Equity Financing
May 18, 2005
|
|
|
BioMimetic Pharmaceuticals Raises $25.7 Million in Series C Financing
Nov. 4, 2004
|
|
|
BioMimetic Pharmaceuticals' Receives Approvable Recommendation from FDA Advisory Panel for GEM 21S®
July 15, 2004
|
|
|
BioMimetic Pharmaceuticals Announces Additions to Senior Management Team
Feb. 12, 2004
|
|
|
BioMimetic Pharmaceuticals and Luitpold Pharmaceuticals Establish Strategic Alliance
Jan. 8, 2003
|
|
|
Orthovita and BioMimetic Enter into a Supply Agreement
Aug. 21, 2002
|
|
|
BioMimetic Pharmaceuticals, Inc. receives investment from Novo A/S
June 25, 2001
|
|
|
BioMimetic Pharmaceuticals, Inc. Raises $6.5 Million in Venture Funding
May 17, 2001
|
|
|
BioMimetic Pharmaceuticals, Inc. Signs Agreements with Harvard Medical School and ZymoGenetics
June 5, 2001
|
|
|
